metricas
covid
Buscar en
Enfermería Clínica
Toda la web
Inicio Enfermería Clínica The one year survival rate of lung adenocarcinoma patients treated with chemothe...
Información de la revista
Vol. 30. Núm. S4.
First International Conference on Nutrition and Public Health (ICNPH-2019)
Páginas 456-460 (junio 2020)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 30. Núm. S4.
First International Conference on Nutrition and Public Health (ICNPH-2019)
Páginas 456-460 (junio 2020)
The one year survival rate of lung adenocarcinoma patients treated with chemotherapy or targeted therapy
Visitas
1
Fidiyah Rusdia,
Autor para correspondencia
, Harun Iskandarb, Tutik Hardjiantic, Syakib Bakrid, Wasis Udayae, Hasyim Kasimd, Erwin Ariefb, Arifin Sewengf
a Internal Medicine Department, Hasanuddin University, Indonesia
b Pulmonology and Respiratory Division of Internal Medicine Department, Hasanuddin University, Indonesia
c Medical Hematology and Oncology Division of Internal Medicine Department, Hasanuddin University, Indonesia
d Kidney and Hypertension Division of Internal Medicine Department, Hasanuddin University, Indonesia
e Geriatrics Division of Internal Medicine Department, Hasanuddin University, Indonesia
f Biostatistics Department, Hasanuddin University, Indonesia
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (2)
Tablas (5)
Table 1. Distribution of sample characteristics (n=100).
Table 2. One-year survival table.
Table 3. Survival by therapy.
Table 4. Survival by drug type in chemotherapy.
Table 5. Survival by drug type in all samples.
Mostrar másMostrar menos
Abstract
Background

Adenocarcinoma is the most common of lung Cancer. The treatment for early stage of lung Adenocarcinoma (I, II) is surgery. Targeted therapy is given to lung Adenocarcinoma patients with EGFR-TKI mutations. Chemotherapy is given to lung Adenocarcinoma patients without EGFR-TKI mutations.

Objective

To compare one-year survival of lung Adenocarcinoma patients treated with chemotherapy or targeted therapy.

Methods

This was a prospective study. The subjects were 100 patients with lung Adenocarcinoma.

Results

1-year Survival of lung Adenocarcinoma patient for one year was 18%. 1-year survival in patients with targeted therapy was higher than chemotherapy, which was 24% vs 9% (p<0.01). 1-Year survival in chemotherapy patients with Carboplatin combined with Vinorelbin was higher than in other chemotherapy drugs (p>0.05). 1-Year survival in patients with Erlotinib drug was 45% highest survival rate compared to chemotherapy drugs and other targeted therapy (p<0.05). Patients receiving Erlotinib (45%) has the highest survival compared to all types of therapy.

Conclusion

Lung Adenocarcinoma patients receiving Erlotinib significantly had the highest survival rate compared to all other targeted therapy drugs and all types of chemotherapy drugs.

Keywords:
Adenocarcinoma
EGFR
Chemotherapy
Targeted therapy

Artículo

Opciones para acceder a los textos completos de la publicación Enfermería Clínica
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Suscribirse
Suscribirse a:

Enfermería Clínica

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos